News | April 15, 2025
Biocon Biologics secures market entry date for Yesafili in US
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Padmanabhan brings over two decades of extensive experience in FMCG sector
The product will be launched in Q1FY26
The company does not expect this development to have any material impact on the current business operations
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Strengthening capabilities in Peptide Therapeutics and CDMO services
The board of directors accepted Hrosz’s resignation and expressed appreciation for his significant contributions during his tenure
Subscribe To Our Newsletter & Stay Updated
